Medtronic appoints new chief medical officer for digital surgery and robotics
Medtronic is bringing on a new chief medical officer for its digital and robotics teams, who it described as one of the top five robotic surgeons in the U.S.
All Posts in "News Team"
Neurocrine’s bid to save schizophrenia prospect fails
Neurocrine Biosciences’ schizophrenia program pivot has failed. The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of luvadaxistat.
FDA greenlights over-the-counter hearing aid features for Apple’s AirPods
After Apple previewed the technology earlier this week, the FDA has now given the green light to the hearing aid features of its premium AirPods.
Oncternal folds all clinical trials after lackluster data drop, patient death
Cancer company Oncternal Therapeutics is folding all its clinical trials and laying off staff, turning its energy toward exploring strategic alternatives such as asset sales, a merger or acquisition.
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs
It’s an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public with fine-tuned offerings.
FDA pushed to be more open, collaborative to accelerate rare disease R&D
The FDA should be more open and collaborative to unleash a surge in approvals of rare disease drugs, according to a report by the National Academies of Sciences, Engineering, and Medicine.
In wake of Q2 revenue drop, Charles River cuts 3% of workforce
In the wake of a second quarter that saw revenues decline by 3.2%, contract research organization Charles River Laboratories is laying off 3% of its workforce, a spokesperson confirmed to Fierce Biotech in an emailed statement.
Inflammatix collects $57M as it awaits FDA review of infectious disease test
With its infectious disease blood test currently under review at the FDA, Inflammatix has obtained $57 million in new financing to help it gear up for its pending commercial rollout.
Sanofi’s $80M bet on Fulcrum’s dystrophy drug ends in phase 3 failure after 4 months
Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure.
European oncology organization extends clinical trial partnership with Medidata
The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is extending a partnership with Medidata for another four years, according to a Sept. 11 release.
Weekly Market Review – December 21, 2024
Medtronic appoints new chief medical officer for digital surgery and robotics
Neurocrine’s bid to save schizophrenia prospect fails
FDA greenlights over-the-counter hearing aid features for Apple’s AirPods
Oncternal folds all clinical trials after lackluster data drop, patient death
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs
FDA pushed to be more open, collaborative to accelerate rare disease R&D
In wake of Q2 revenue drop, Charles River cuts 3% of workforce
Inflammatix collects $57M as it awaits FDA review of infectious disease test
Sanofi’s $80M bet on Fulcrum’s dystrophy drug ends in phase 3 failure after 4 months